Algernon Health Inc.

About Algernon Health Inc.

Algernon Pharmaceuticals Inc. is a clinical-stage Canadian drug development and repurposing company focused on investigating drugs and naturally occurring compounds for unmet global medical needs. Their mission is to discover new therapeutic uses for off-patent drugs with established safety profiles, using a cost-effective and capital-efficient model.

Products & Services

NP-251 (Repirinast):Originally an asthma drug, now being repurposed for chronic kidney disease after showing a 50% reduction in fibrosis in preclinical models.

AP-188 (DMT):N,N-Dimethyltryptamine, a naturally occurring compound, investigated as a potential treatment for stroke and traumatic brain injury (TBI) by inducing neuroplasticity.

NP-120 (Ifenprodil):Research program for chronic cough and idiopathic pulmonary fibrosis, acquired by Seyltx Inc. in March 2024 for USD $2M and a 20% equity position.

Specialties

Drug Repurposing Neuroplasticity Research Chronic Kidney Disease Treatment Stroke and Traumatic Brain Injury Treatment Alzheimer's Diagnostics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 500000 MR: - FA: $500,000 FAN: 500000	D: 2025-11-06 FD: 2025-11-06	-

Private Placement Latest

2025-11-06

$500K

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Rick Strassman

Clinical Associate Professor of Psychiatry

D

David Nutt

Edmund J. Safra Professor of Neuropsychopharmacology

E

Ede Frecska

Chairman of Psychiatry at the Faculty of Medicine of the University of Debrecen

S

Slawek Wojtowicz

Medical & Scientific Advisor

L

Luis Eduardo Luna

E

Ervin Laszlo

View 18 more team members with Pro

Unlock Full Team Directory

Recent News